Scholar Rock Holding Corp

D

الأسعار متأخرة 15 دقيقة

القطاع: Healthcare

الصناعة: Biotechnology

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.